Magnetic Resonance Spectroscopy in the Diagnosis of Dementia with Lewy Bodies

Dementia with Lewy bodies (DLB) is considered to be the second most frequent primary degenerative dementing illness after Alzheimer’s disease (AD). DLB, together with Parkinson’s disease (PD), Parkinson’s disease with dementia (PDD) belong toα-synucleinopathies—a group of neurodegenerative diseases associated with pathological accumulation of theα-synuclein protein. Dementia due to PD and DLB shares clinical symptoms and neuropsychological profiles. Moreover, the core features and additional clinical signs and symptoms for these two very similar diseases are largely the same. Neuroimaging seems to be a promising method in differential diagnosis of dementia studies. The development of imaging methods or other objective measures to supplement clinical criteria for DLB is needed and a method which would accurately facilitate diagnosis of DLB prior to death is still being searched. Proton magnetic resonance spectroscopy (1H-MRS) provides a noninvasive method of assessing anin vivobiochemistry of brain tissue. This review summarizes the main results obtained from the application of neuroimaging techniques in DLB cases focusing on1H-MRS.

Download Full-text

Proton magnetic resonance spectroscopy of the striatum in Parkinson's disease patients with motor response fluctuations

Parkinsonism & Related Disorders ◽

10.1016/1353-8020(96)00007-7 ◽

1996 ◽

Vol 2 (2) ◽

pp. 63-67 ◽

Cited By ~ 15

Author(s):

K.Ray Chaudhuri ◽

G.M. Lemmens ◽

S.C.R. Williams ◽

C. Ellis ◽

C.M. Lloyd ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Magnetic Resonance ◽

Magnetic Resonance Spectroscopy ◽

Proton Magnetic Resonance ◽

Motor Response ◽

Proton Magnetic Resonance Spectroscopy ◽

Resonance Spectroscopy

Download Full-text

Dementia with Lewy bodies and Parkinson’s disease dementia

10.1093/med/9780199644957.003.0035 ◽

2013 ◽

Cited By ~ 1

Author(s):

Arvid Rongve ◽

Dag Aarsland

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Dementia With Lewy Bodies ◽

Clinical Symptoms ◽

Imaging Techniques ◽

Lewy Bodies ◽

Epidemiological Data ◽

Parkinson’S Disease Dementia ◽

Esterase Inhibitors ◽

Staging Systems

Dementia with Lewy bodies and Parkinson’s disease dementia belong to the α-synucleinopathies, a family of diseases pathologically characterized by aggregation of α-synuclein in Lewy bodies in the brain. In this chapter we present the epidemiological data for both conditions including new data on MCI. Clinical diagnostic criteria are reviewed and the different neuropathology staging systems for DLB and PDD and the most important genetic findings are considered. Biomarkers in DLB and PDD with particular focus on imaging techniques like CIT-SPECT and MRI are described. Important clinical symptoms in both conditions are presented in detail and the most important clinical differential diagnoses are discussed. Pharmacological and non- pharmacological treatment of different symptoms in both conditions are discussed with particular emphasis on the choline esterase inhibitors and antipsychotic medications.New data on memantine are presented.

Download Full-text

Assessment of genetic risk for improved clinical-neuropathological correlations

Acta Neuropathologica Communications ◽

10.1186/s40478-020-01033-1 ◽

2020 ◽

Vol 8 (1) ◽

Author(s):

Barbara E. Spencer ◽

Robin G. Jennings ◽

Chun C. Fan ◽

James B. Brewer

Keyword(s):

Alzheimer’S Disease ◽

Parkinson’S Disease ◽

Alzheimer's Disease ◽

Parkinson's Disease ◽

Genetic Risk ◽

Dementia With Lewy Bodies ◽

Lewy Bodies ◽

Pathological Diagnosis ◽

Polygenic Score ◽

Diagnosis Of Dementia

Abstract In the clinical diagnosis of dementia with Lewy bodies, distinction from Alzheimer’s disease is suboptimal and complicated by shared genetic risk factors and frequent co-pathology. In the present study we tested the ability of polygenic scores for Alzheimer’s disease, dementia with Lewy bodies, and Parkinson’s disease to differentiate individuals in a 2713-participant, pathologically defined sample. A dementia with Lewy bodies polygenic score that excluded apolipoprotein E due to its overlap with Alzheimer’s disease risk was specifically associated with at least limbic (transitional) Lewy-related pathology and a pathological diagnosis of dementia with Lewy bodies. An Alzheimer’s disease polygenic score was associated with neuritic plaques and neurofibrillary tangles but not Lewy-related pathology, and was most strongly associated with an Alzheimer’s pathological diagnosis. Our results indicate that an assessment of genetic risk may be useful to clinically distinguish between Alzheimer’s disease and dementia with Lewy bodies. Notably, we found no association with a Parkinson’s disease polygenic score, which aligns with evidence that dementia with Lewy bodies has a distinct genetic signature that can be exploited to improve clinical diagnoses.

Download Full-text